

INTERACTIVE SYSTEM DESIGN

FINAL REPORT

Project: Drug to Drug Interaction Knowledge Base (DIKB)

Group Members: Xi Peng

Danchen Zhang

Yu Zhang

Date: December 10th, 2014

Phase1: User Study

For the first time of our meeting, we prepared a few questions for our client. It includes the background and details of the project. One person in our group was in charge of asking questions and the other two recorded the client's answers.

Background

- **The purpose of this website**

Provide drug – drug interaction information from publicity available resource and the database their research team has. His research team spent many years with drug experts for collecting about 70 kinds of drugs. Those accurate drug-drug interactions are mainly for heart diseases and stroke. This website is a part of DIBK program.

- **Who are the real users of this website**

The pharmacists, clinics and researchers and patients

- **How long does version 1.2 has been used**

The version 1.2 was created by Dr. Boyce as his PhD dissertation. Because the time limitation, he didn't create a friendly user interface or arrange the data layouts.

- **How do the clients feel about version 1.2**

He started working on this project after his PhD degree. His team is still doing more research on more drugs. He needs a dynamic user interface for the user to do manipulations and need us to figure out a way to arrange the data.

- **What's their advice**

We can work with his team, based on everything he has now. But we have learned some new technology, such as the architecture they are using. After we design the user interface, Dr. Hochhesier will discuss with us.

- **Is there any other similar website for the clients**

No. This is going to be the first drug-drug interaction knowledge base in the world.

Function

- **What kind of interface do client prefer (color, logo, style, how many contents, frame, menu, banner, pictures)**

The functions are really important. The website has to be simple, easy to manipulate and dynamic. Most of the users are phamisisitis, clicnics and patients, they don't have that much knowledge about techonicals. They need to find the information in a short time. The website logo will be designed by us, it has to include "DIKB" sign.

All the information about interactions are messed up now, we need to redo the data schema and delete the duplications.

- **What are the main functions**

Search the drug-drug interactions by kinds of categories, such as drug names(generic name or brand name), drug ID or drug class.

There should be different interfaces for patients or professionals. The patients are able to see the drug name and interactions, however, the professionals are able to check the assertions, evidence and dataset sources. How to sort those interactions and assertions to make them more clear is very important. Maybe we need to design an algorithm for the schema, so we are able to sort the data by various ways.

- **Special Function: searching history**

It's not necessary.

- **Based on the previous version, what functions do the clients want to keep and what do the clients want to modify**

They want to rebuild a new one.

- **Do we need to create another admin user for volunteer in the community**

No, it's going to be a function of the website.

- **Website Language : HTML5, D3, Python**

Java Library: JQuery

Architecture: Web2py, MVC

- **Details about information visualization techniques (mapping, graphics)**

Because the data are dynamic, they phmasists want to know what part has been updated and what part has been changed. This techonoly can make it more clear and easy to figure out.

Phase2: Task Analysis

User Scenario

Before the mock-up, we created this user scenario to help us understand the users. The four users in this scenario represent the main user group of the website.

Because we don't have the opportunity to get to know all the professional users and they are not really close to our life, we did some background researches on professional users. First, we researched some daily work logs about professional users. The logs gave us the details about their work, especially the problems occurred during work period. Second, we integrated that information with Dr. Boyce research report in 2005 and updated new users' information. Last but not least, we tried some drug websites. That helped us get to know the professionals custom of navigating the drug websites. In the meanwhile, we collected all the weakness and strength of the websites.

According to our researches, we had an idea on why those professional users need DIKB, how they like do to use DIKB and what are their expectations about DIKB. Then we came up with this user scenario with Dr. Hochheiser, who has work experience in technical and medical. Dr. Hochheiser is also a leader of DIKB user interface design group.

User 1 – Patients

Mike is a college student. He got flu last week and started taking some medicine. Recently, he has some problems with his sleep. He got some sleeping pills from CVS, but he didn't understand what says on the drug label. Because he was worried

about the drug side effects, he tried to seek information on the safety of the medicines.

He came to DIKB website, typed the drug names and concluded the drugs are safe. On the website, he found a function called "create report" which told him drug interactions with alcohols, food, beverages or tobaccos. He added his drug names, clicked the "create a report" button, and then printed out the report as references.

User2 –Researchers in Drug Development

Sara is a researcher. Her job is to help clinicians guide patients to safe and effective medication therapies. When she creates the medication therapies, she would like to have all the drug names and interactions which will occur with one specific drug. Sometimes, she also needs to know where the interactions resources come from and how reliable they are. If she can save all the resources as electronic version, it's more convenient for her work.

She opened DIKB website, typed in one drug name, then she got a lists of other drugs names and interactions which will occur with this drug. It's alphabetically by default. On the tab, it classified as major interactions, moderate interactions and minor interactions. After she clicked the drug names, the interactions detail popped up. Because those are for patients not professionals, she checked the box "professionals" and got the assertions and evidence for the same drugs.

User3 –Drug- Safety Scientists

Dr. Miller is a professional hospital drug-safety scientist who identifies reports and follows up on adverse effects of drugs for the hospital every day. Then he needs to send the repots to regulatory agencies. He has to check different materials from different places to ensure the products are released safely. Every day he spends a lot of time on going back and forth between different websites or books.

He opened DIKB website and read the website instruction. He typed the drug class names as examples and checked "professionals" box. All the assertions related to the drug showed up. Then he added another drug and got the assertions for those two drugs. According to the instruction, he clicked the dataset tab, all the data sources were listed there, such as drug agencies or drug attributes.


User4 – Clinicians

Dr. Juicy prescribes a large range of medications every day. When she looks after patients who are taking medications prescribed by other doctors (specialized doctors), she needs to know the effects of all the medications in a short time. However, some of prescribed drugs are not belong to her field which means she is not always familiar with. It will be too much information for her if she has to remember them all. She hopes to find a tool to help her find all the reliable sources in a reliable way and gives the patients some suggestions on drugs. Because of her major, she prefers to use trade names (class name) to search.


She came to DIKB website and clicked "how it works" which offers the instruction of the website first. Then she checked "professionals" box, typed in the drug class names and got the assertions. Under the assertion, there were four evidences listed which helped her to offer a better prescription to her patient. Then she created a report for the patient, including those drugs interaction with food, beverages, alcohols and caffeine. She clicked the pint button and attached the repot with prescription.

Hierarchical Task Analysis


Below is the hierarchical task analysis we made, based on the information we got from our client (Dr. Boyce).



Phase3: Work-Flow



Phase4: Mock-Up



DIKB

Integrated resource about drug to drug interaction

**For Help
Contact Us**

Drug Interaction Knowledge Base (DIKB) is an evidence-focused knowledge base designed to support pharmacoepidemiology and clinical decision support. It contains quantitative and qualitative assertions about drug mechanisms and pharmacokinetic drug-drug interactions for over 60 drugs.

Examples: amoxicillin, ibuprofen, etc [how it works](#)

Patient-Relevant

[20 most common diseases](#)

Clinically-Relevant

[The University of Pittsburgh Linked Structured Product Label repository.](#)
[The University of Pittsburgh Pharmacokinetic Drug-drug Interaction \(PK DDI\) Package Insert Corpus](#)
[The DIKB evidence taxonomy within the NCBO Annotator](#)

Recent Publications from the DIKB Project

[Summary of the DIKB project](#)
[Modeling Arguments in Scientific Papers](#)
[The inclusion criteria for evidence entered into the DIKB and other information](#)



DIKB

Integrated resource about drug to drug interaction

For Help
Contact Us

Drug Interaction Knowledge Base (DIKB) is an evidence-focused knowledge base designed to support pharmacoepidemiology and clinical decision support. It contains quantitative and qualitative assertions about drug mechanisms and pharmacokinetic drug-drug interactions for over 60 drugs.

ab

Abilify (aripiprazole) [how it works](#)

Abraxane (paclitaxel protein-bound)

Abreva (docosanol topical)

Abilify Maintena (aripiprazole)

Absorica (isotretinoin)

Abstral (fentanyl)

Abelcet (amphotericin b lipid complex)

Abilify Discmelt (aripiprazole)

Abbokinase (urokinase)

Patient-Relevant

[20 most common diseases](#)

Clinically-Relevant

[The University of Pittsburgh ABC Plus Senior](#) (multivitamin with minerals) [PDF](#)

[The University of Pittsburgh Pharmacokinetic Drug-Drug Interaction \(PK DDI\) Package Insert Corpus](#)

[The DIKB evidence taxonomy within the NCBO Annotator](#)

Recent Publications from the DIKB Project

[Summary of the DIKB project](#)

[Modeling Arguments in Scientific Papers](#)

[The inclusion criteria for evidence entered into the DIKB and other information](#)



DIKB

Integrated resource about drug to drug interaction

For Help
Contact Us

☐ Professionals

type in a drug name (brand name, generic name) or drug ID

Abilify aripiprazole

☐ Generic Only ☐ Brand Only

Currently displaying 916 drugs known to interact with Abilify (aripiprazole)

[A](#) [B](#) [C](#) [D](#) [E](#) [F](#) [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#) [U](#) [V](#) [W](#) [X](#) [Y](#) [Z](#)

- | | |
|--|---|
| <input checked="" type="checkbox"/> A-Cof DH (guaifenesin / hydrocodone) | <input checked="" type="checkbox"/> Allergy Multi-Symptom (acetaminophen / chlorpheniramine / phenylephrine) |
| <input checked="" type="checkbox"/> A-G Tussin (chlorpheniramine / hydrocodone / pseudoephedrine) | <input checked="" type="checkbox"/> Allergy Pain Relief (acetaminophen / chlorpheniramine / phenylephrine) |
| <input checked="" type="checkbox"/> A-Phedrin (pseudoephedrine / triprolidine) | <input checked="" type="checkbox"/> Allergy Relief (chlorpheniramine) |
| <input checked="" type="checkbox"/> A-Spas S / L (hyoscyamine) | <input checked="" type="checkbox"/> Allergy Relief D (cetirizine / pseudoephedrine) |
| <input checked="" type="checkbox"/> A-Spas (hyoscyamine) | <input checked="" type="checkbox"/> Allergy Sinus Maximum Strength (acetaminophen / chlorpheniramine / pseudoephedrine) |
| <input checked="" type="checkbox"/> A-Tan 12X (guaifenesin / phenylephrine / pyrilamine) | <input checked="" type="checkbox"/> Allergy Sinus PE Pain Relief (acetaminophen / chlorpheniramine / phenylephrine) |
| <input checked="" type="checkbox"/> Abatuss DMX (dexchlorpheniramine / dextromethorphan / pseudoephedrine) | <input checked="" type="checkbox"/> Allergy Time (chlorpheniramine) |
| <input checked="" type="checkbox"/> abiraterone | |
| <input checked="" type="checkbox"/> Abstral (fentanyl) | |



DIKB

Integrated resource about drug to drug interaction

For Help
Contact Us

☐ Professionals

type in a drug name (brand name, generic name) or drug ID

Add

Abilify

aripiprazole

✕

Remove All

Clopine

clozapine

✕

Overview

Interactions

Create a Report

All Interactions

Major Interactions

Moderate Interactions

Minor Interactions

☒ Generic Only

☐ Brand Only

Currently displaying 20 drugs known to interact with Abilify (aripiprazole) & Clopine (clozapine)

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

clonazepam

clonazepam

gabapentin

gabapentin

levothyroxine

levothyroxine

lisinopril

lisinopril

Lyrica (pregabalin)

metformin

metformin

omeprazole

omeprazole

tramadol

tramadol

trazodone

trazodone

Vitamin D3 (cholecalciferol)



DIKB

Integrated resource about drug to drug interaction

For Help
Contact Us

☐ Professionals

type in a drug name (brand name, generic name) or drug ID

Add

Abilify

aripiprazole

✕

Remove All

Clopine

clozapine

✕

Overview

Interactions

Create a Report



MODERATE

clonazepam ↔ aripiprazole

Applies to: clonazepam and Abilify (aripiprazole)

Using **clonazepam** together with **aripiprazole** may increase side effects such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience some impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with these medications. Avoid driving or operating hazardous machinery until you know how the medications affect you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.



DIKB

Integrated resource about drug to drug interaction

For Help
Contact Us

☐ Professionals

type in a drug name (brand name, generic name), drug ID or drug class

Abilify	aripiprazole	✖	<input type="button" value="Remove All"/>
Clopine	clozapine	✖	

Overview Interactions **Create a Report**

Select the interactions to include the report

Print

- ☒ Caffeine
- ☐ Ethanol/Alcohol
- ☐ Tobacco
- ☐ Beverage
- ☐ Food



DIKB

Integrated resource about drug to drug interaction

For Help
Contact Us

☐ Professionals

type in a drug name (brand name, generic name), drug ID or drug class

Abilify	aripiprazole	✖	<input type="button" value="Remove All"/>
Clopine	clozapine	✖	

Overview Interactions **Create a Report**

Select the interactions to include the report

Print

- ☒ Caffeine
- ☐ Ethanol/Alcohol
- ☐ Tobacco
- ☐ Beverage
- ☐ Food

Drug interactions report for the following medications:

Abilify Clopine

Drug to Drug Interactions

No clinically significant drug-drug interactions are expected.

Drug-Caffeine interactions are found

Caffeine (Enerjets® | Top Care Stay Awake Maximum Strength | Stay Awake® | Awake | .44 Magnum™ | Mollie® | Overtime® | Stay Awake | 357 HR Magnum® | Cafcit® | Alert® | Fastlane® | Waykup®)

While taking Caffeine products, limit the use of foods, beverages, herbs and other medicines that contain additional caffeine, like coffee, teas, colas, chocolate and some diet pills. Grapefruit juice or grapefruit may also increase the effects of Caffeine.



DIKB

Integrated resource about drug to drug interaction

For Help
Contact Us

☒ Professionals

type in a drug name (brand name, generic name) or drug ID

Add

Metabolism



Remove All

Overview

Assertions

Dataset

Create a Report for Patients

All Assertions

Major Assertions

Moderate Assertions

Minor Assertions

1-methylxanthine has metabolite 1-methyluric-acid

14-hydroxycclarithromycin maximum concentration continuous value



DIKB

Integrated resource about drug to drug interaction

For Help
Contact Us

☒ Professionals

type in a drug name (brand name, generic name) or drug ID

Add

Metabolism



Remove All

Methylxanthine



Overview

Assertions

Dataset

Create a Report for Patients

Evidence 1:

Evidence Type: Non_traceable_Drug_Label_Statement

Quote: Metabolism Following oral dosing, theophylline does not undergo any measurable first-pass elimination. In adults and children beyond one year of age, approximately 90% of the dose is metabolized in the liver. Biotransformation takes place through demethylation to 1-methylxanthine and hydroxylation to 1,3-dimethyluric acid. 1-methylxanthine further hydroxylated, by xanthine oxidase, to 1-methyluric acid. About 6% of a theophylline dose is N-methylated to caffeine. Theophylline demethylation to 3-methylxanthine is catalyzed by cytochrome P-450 1A2, while cytochromes P-450 2E1 and P-450 3A3 catalyze the hydroxylation to 1,3-dimethyluric acid. Demethylation to 1-methylxanthine appears to be catalyzed either by cytochrome P-450 1A2 or a closely related cytochrome. In neonates, the N-demethylation pathway is absent while the function of the hydroxylation pathway is markedly deficient. The activity of these pathways slowly increases to maximal levels by one year of age.

Pointer: heophylline-3M-082006

Reviewer: Boycer

Assumptions: -

- ▼ Assertion 1
 - Evidence 1.1
 - Evidence 1.2
- ▼ Assertion 2
 - Evidence 2.1



DIKB

Integrated resource about drug to drug interaction

For Help
Contact Us

☒ Professionals

type in a drug name (brand name, generic name) or drug ID

Add

Metabolism



Remove All

Methylxanthine



Overview

Assertions

Dataset

Create a Report for Patients

Metabolism	Credible Meds	NDF-RT	ONC High Priority	ONC Non- Interrupti ve	OSCAR	DDI Corpus 2011	DDI Corpus 2013	PK DDI Corpus	NLM DDI Corpus	KEGG	TWO- SIDES	Drug- Bank	DIKB	Sem MedDB
Methylxanthine														
confidence value											X			
description	X					X	X		X			X	X	
clinical effect	X				X			X			X			
citation of evidence					X			X					X	X
management options	X													
mechanism	X									X		X	X	
precipitant/object distinction	X		X	X	X			X					X	
related drugs	X													
severity concept		X	X	X	X					X				

Phase5: Final Version



DIKB

Integrated resource about drug to drug interaction

For Help

Contact Us

☐ Professional

Drug Interaction Knowledge Base (DIKB) is an evidence-focused knowledge base designed to support pharmacoepidemiology and clinical decision support. It contains quantitative and qualitative assertions about drug mechanisms and pharmacokinetic drug-drug interactions for over 60 drugs.

type in drug, brand or generic name.

Add

Example: Abilify, Isotretinoin, etc.

[Patient-Relevant](#)

[Recent Publications from the DIKB Project](#)

[Most common diseases](#)

[Summary of the DIKB project](#)

[Modelling Arguments in Scientific Papers](#)

[The inclusion criteria for evidence entered into the DIKB and other information](#)

[Recent Publications from the DIKB Project](#)

[The University of Pittsburgh Linked Structured Product Label Repository](#)

[The University of Pittsburgh Drug-drug Interaction \(PK DDI\) Package Insert Corpus](#)

[The DIKB evidence taxonomy within the NCBO Annotator](#)



DIKB

Integrated resource about drug to drug interaction

[For Help](#)

[Contact Us](#)

☐ Professional

type in drug, brand or generic name.

Add

Example: Abilify, Isotretinaion, etc.

Abilify ✖

[Remove all](#)

Overview

Interaction

Create a report

☒ Show Generic Name

☒ Show Brand Name

☐ 60 interactions

☒ 32 major interactions

☐ 12 moderate interactions

☐ 16 minor interactions

☒ _A-Cof DH(guaifenensin / hydrocodone)

☐ _A_G Tussion (chlorpheniramine / hydrocodone)

☒ _A-Phedrin (pseudoephedrine / triprolidine)

☐ _A-Spas S / L (hyoscyamine)

☒ _A-Tan 12X (guaifenesin / phenylephrine / pyrilamine)

☒ _Abatuss DMX (dexchlorpheniramin / dextromethorphan / pseudoephedrine)



DIKB

Integrated resource about drug to drug interaction

[For Help](#)

[Contact Us](#)

☐ Professional

type in drug, brand or generic name.

Add

Example: Abilify, Isotretinaion, etc.

Abraxane ✖
Abilify ✖

[Remove all](#)

Overview

Interaction

Create a report

☒ Show Generic Name

☒ Show Brand Name

☐ 60 interactions

☒ 32 major interactions

☐ 12 moderate interactions

☐ 16 minor interactions

☒ _A-Cof DH(guaifenensin / hydrocodone)

☐ _A_G Tussion (chlorpheniramine / hydrocodone)

☒ _A-Phedrin (pseudoephedrine / triprolidine)

☐ _A-Spas S / L (hyoscyamine)

☒ _A-Tan 12X (guaifenesin / phenylephrine / pyrilamine)

☒ _Abatuss DMX (dexchlorpheniramin / dextromethorphan / pseudoephedrine)



DIKB

Integrated resource about drug to drug interaction

[For Help](#)
[Contact Us](#)

☒ Professional

Add

Example: Abilify, Isotretinoin, etc.

Abraxane ✖
 Abilify ✖

Remove all

Overview

Assertion

Create a report for the patient

Evidence 1:

Evidence Type: Non_traceable_Drug_Label_Statement

Quote: Metabolism Following oral dosing, theophylline does not undergo any measurable first-pass elimination. In adults and children beyond one year of age, approximately 90% of the dose is metabolized in the liver. Biotransformation takes place through demethylation to 1-methylxanthine and 3-methylxanthine and hydroxylation to 1,3-dimethyluric acid. 1-methylxanthine is further hydroxylated, by xanthine oxidase, to 1-methyluric acid. About 6% of a theophylline dose is N-methylated to caffeine. Theophylline demethylation to 3-methylxanthine is catalyzed by cytochrome P-450 1A2, while cytochromes P-450 2E1 and P-450 3A3 catalyze the hydroxylation to 1,3-dimethyluric acid. Demethylation to 1-methylxanthine appears to be catalyzed either by cytochrome P-450 1A2 or a closely related cytochrome. In neonates, the N-demethylation pathway is absent while the function of the hydroxylation pathway is markedly deficient. The activity of these pathways slowly increases to maximal levels by one year of age.

Evidence 1

Evidence 2

Evidence 3

Evidence 4

Phase6: Summary of DIKB Project

In the design part, we start with a good understanding of users. The understanding comes about primarily through researches, previous documentations and people who are often aware of the users' true needs and difficulties. We provide instructions, help button and error checking on all pages. In case something goes wrong, the website will take the proper actions or guide the users what to do.

In the demo website, we implemented what we planned except applying D3 on the dataset page. The user interface design parts took us longer than we thought. We had 5 meetings to discuss about the functions and designs with Dr. Boyce and Dr. Hochheiser. The website is a part of the whole DIKB project, we try to finalize the website design and creates more functions, so that they are able to process it later.

It's a really nice opportunity that we could work with real client for a real project. We set up every Tuesday as our meeting time with Dr. Boyce and Dr. Hochheiser to update our progress and modify our designs and website. We had a great time working as team with each other and professionals.

Even though it's only a month, we practiced a lot what we learn from class and acknowledged some professional skills on user design and website design. Thank you very much for the interesting subject and the opportunity offered by Dr. Brusilovsky in his class. It's the best final we've had.